Growth Metrics

Travere Therapeutics (TVTX) Net Margin (2016 - 2024)

Historic Net Margin for Travere Therapeutics (TVTX) over the last 12 years, with Q4 2024 value amounting to 0.01%.

  • Travere Therapeutics' Net Margin rose 35100.0% to 0.01% in Q4 2024 from the same period last year, while for Sep 2025 it was 0.0%, marking a year-over-year increase of 12500.0%. This contributed to the annual value of 0.39% for FY2024, which is 1828100.0% down from last year.
  • As of Q4 2024, Travere Therapeutics' Net Margin stood at 0.01%, which was up 35100.0% from 0.16% recorded in Q3 2024.
  • Over the past 5 years, Travere Therapeutics' Net Margin peaked at 646.92% during Q3 2023, and registered a low of 238.55% during Q4 2020.
  • Moreover, its 5-year median value for Net Margin was 0.08% (2024), whereas its average is 19.29%.
  • In the last 5 years, Travere Therapeutics' Net Margin skyrocketed by 5956100bps in 2023 and then tumbled by -6470800bps in 2024.
  • Quarter analysis of 5 years shows Travere Therapeutics' Net Margin stood at 238.55% in 2020, then skyrocketed by 124bps to 56.1% in 2021, then grew by 20bps to 67.53% in 2022, then plummeted by -105bps to 3.5% in 2023, then skyrocketed by 100bps to 0.01% in 2024.
  • Its Net Margin was 0.01% in Q4 2024, compared to 0.16% in Q3 2024 and 1.4% in Q2 2024.